EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Potential of Single‐Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics

Getachew Gezehagn Kussia iD, Tesfaye Sisay Tessema iD

Journal of Immunology Research · 2024-01 · 2024 (1)

DOI: 10.1155/2024/1804038 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, online erschienen am 09.08.2024. Verfasst von Getachew Gezehagn Kussia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Genomics and Bioinformatics Bio and Emerging Technology Institute, Addis Ababa 5954, Ethiopia. Hauptthemen laut MEDLINE: Single-Chain Antibodies, Biological Products. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advancement of genetic engineering has revolutionized the field of immunology by allowing the utilization of intrinsic antibody structures. One of the biologics that are being produced by recombinant antibody technology is single‐chain fragments variable (scFv). Genes of variable regions, the heavy and light chains that are genetically linked into a single transcript by a short flexible linker peptide, are used to generate this fragment from cellular and synthetic libraries. The specificity and affinity of these molecules are comparable to those of parental antibodies. Fusion with marker proteins and other potent molecules improves their stability, circulation half‐life, activity, and efficient purification. Besides, this review comprises construction protocols, therapeutics, and diagnostic applications of scFv, as well as related challenges. Nonetheless, there are still issues with efficacy, stability, safety, intracellular administration, and production costs that need to be addressed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Chain AntibodiesBiological ProductsHumansAnimalsGenetic EngineeringProtein Engineering

Substanzen

Single-Chain AntibodiesBiological Products

Autor:innen und Institutionen

  • Genomics and Bioinformatics Bio and Emerging Technology Institute, Addis Ababa 5954, Ethiopia.
  • Institute of Biotechnology Addis Ababa University, Addis Ababa 1176, Ethiopia.

ORCID-Profile: Getachew Gezehagn Kussia, Tesfaye Sisay Tessema

Zitieren

APA

Gezehagn Kussia, G., & Tessema, T. S. (2024). The Potential of Single‐Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics. Journal of Immunology Research, 2024(1). https://doi.org/10.1155/2024/1804038

Vancouver

Gezehagn Kussia G, Tessema TS. The Potential of Single‐Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics. Journal of Immunology Research. 2024;2024(1). doi:10.1155/2024/1804038

BibTeX
@article{GezehagnKussia2024,
  author = {Gezehagn Kussia, Getachew and Tessema, Tesfaye Sisay},
  title = {The Potential of Single‐Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics},
  journal = {Journal of Immunology Research},
  year = {2024},
  volume = {2024},
  number = {1},
  doi = {10.1155/2024/1804038}
}
Kostenlos starten →